Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KA34 in Osteoarthritis of the Knee
NCT03133676Phase 1Completed
- Sponsor
- Calibr-Skaggs Institute for Innovative Medicines
- Start
- May 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing KA34 Active Drug with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started May 2018; status: completed.
02
Drugs
kartogenin
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03133676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03133676.